RE:Red Flags to ConsiderCould be that ONCY realized that the Chinese market for pelareorep in combination with an immune checkpoint inhibitor is far greater than the scope of the Adlai Nortye agreement for pelareorep + chemotherapy (paclitaxel) and the licensing deal was mutually retracted since Adlai Nortye was not large enough to fulfill the increased market potential. No red flags just further opportunity for ONCY since whoever acquires ONCY will be able to decide on how it wants to deal with the China market, if at all, since the US Government's recently passed IRA focused on the treatment of US biologics and China. .
https://www.oncolyticsbiotech.com/press-releases/detail/389/oncolytics-biotech-inc-and-adlai-nortye-enter-into-usd